MedTrace Logo

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-08-12

No results posted yet for this study

Summary

This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).

Conditions

  • Hyperlipidemias
  • Dyslipidemias
  • Elevated Lp(a)

Interventions

DRUG

SLN360

SLN360 for subcutaneous (s.c.) injection

DRUG

Placebo

Sodium chloride for subcutaneous (s.c.) injection

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Silence Therapeutics plc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2023-08-23
Completion
2023-08-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606602 on ClinicalTrials.gov